Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients

NCT06907875 is registered in ClinicalTrials.gov with Epicrispr Biotechnologies, Inc. as lead sponsor.

NCT NCT06907875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06907875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients
Lead sponsor
Epicrispr Biotechnologies, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 8, 2025
Completion date
April 30, 2032
Enrollment
12 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

facioscapulohumeral muscular dystrophy